title: Effect of 3-aminobenzamide on perforation an experimental colitis model.
abstract: OBJECTIVE
  The anti-inflammatory activity of 3-aminobenzamide (3-AB) has been shown via histopathology and immunohistochemistry in various colitis models. We aimed to study the effects of 3-AB on tissue mechanical endurance and, associatively, preventing perforation in colitis.
  
  
  METHODS
  Thirty male Wistar albino rats were randomly divided into three groups. Rectal saline was administered to Group 1 (sham+saline). Rectal trinitrobenzensulphonic acid was applied to induce colitis in Group 2 (colitis+saline) and Group 3 (colitis+3-AB). Groups 1 and 2 were treated intraperitoneally with saline (1 ml every 12 hours) and Group 3 was treated with 3-AB (10 mg/kg every 12 hours). After seven days, rats were sacrificed and colon lipid peroxidation levels, the serum tumor necrosis factor alpha (TNF-α) level, bowel bursting pressures, and bowel wall tensions were measured.
  
  
  RESULTS
  Bowel bursting pressure in Group 2 was significantly lower than in Groups 1 and 3 (p<0.001 for both groups). Bowel wall tension in Group 2 was significantly lower than in Groups 1 and 3 (p<0.001 for both groups). There were no significant differences between groups for serum TNF-α levels. For lipid peroxidation, malondialdehyde (MDA) levels were increased in Groups 2 and 3 compared to Group 1.
  
  
  CONCLUSIONS
  3-AB may aid prevention of perforations that develop in inflammatory bowel disease, requiring surgical treatment.
authors.affiliation: Department of General Surgery, Adana Numune Training and Research Hospital, Adana, Turkey. drebrumenekse@gmail.com.
authors.forename: Ebru
authors.initials: E
authors.lastname: Menekse
authors.forename: Sezai
authors.initials: S
authors.lastname: Aydın
authors.forename: Aylin
authors.initials: A
authors.lastname: Sepici Dinçel
authors.forename: Abdullah
authors.initials: A
authors.lastname: Eroğlu
authors.forename: Mete
authors.initials: M
authors.lastname: Dolapçı
authors.forename: Osman
authors.initials: O
authors.lastname: Yıldırım
authors.forename: Ömer
authors.initials: Ö
authors.lastname: Cengiz
mesh_terms: D000818:Animals; D001549:Benzamides / Q000627:therapeutic use*; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D003106:Colon / Q000293:injuries*; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D007416:Intestinal Perforation / Q000209:etiology / Q000517:prevention & control*; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D011312:Pressure / Q000009:adverse effects; D051381:Rats; D017208:Rats, Wistar; D012421:Rupture / Q000209:etiology / Q000517:prevention & control; D014302:Trinitrobenzenesulfonic Acid; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D001549:Benzamides; D004791:Enzyme Inhibitors; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; C025160:3-aminobenzamide; D014302:Trinitrobenzenesulfonic Acid